# Meletios Α. Dimopoulos

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/meletios-dimopoulos/

## Facts

| Field | Value |
| --- | --- |
| Citations | 130,233 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 160 |
| i10-index | 1,337 |
| Last Known Institution | Korea University |
| OpenAlex ID | https://openalex.org/A5033573338 |
| ORCID iD | https://orcid.org/0000-0001-8990-3254 |
| Works | 2,978 |

## Researcher papers

- [International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma](https://scholariq.org/papers/international-myeloma-working-group-consensus-criteria-for-response-and-minimal/)
- [Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma](https://scholariq.org/papers/lenalidomide-and-dexamethasone-in-transplant-ineligible-patients-with-myeloma/)
- [Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma](https://scholariq.org/papers/oral-selinexor-dexamethasone-for-triple-class-refractory-multiple-myeloma/)
- [Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma](https://scholariq.org/papers/daratumumab-bortezomib-lenalidomide-and-dexamethasone-for-multiple-myeloma/)
- [A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial](https://scholariq.org/papers/a-simplified-frailty-scale-predicts-outcomes-in-transplant-ineligible-patients/)
- [International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation](https://scholariq.org/papers/international-myeloma-working-group-guidelines-for-the-management-of-multiple/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)

## Researcher university

- [Korea University](https://scholariq.org/institutions/korea-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.